AbbVie (ABBV) Stock Could Be 44% Undervalued As Cancer Trial News Lands

AbbVie has delivered strong share price gains in recent years, and the latest drug updates keep the story in the spotlight. The key issue for anyone looking at the stock today is whether that rally is still grounded in the cash it can generate. With the Discounted Cash Flow (DCF) lens in focus, the question is how the current price lines up with the stream of cash flows investors expect AbbVie to produce over time. AbbVie has returned 211.2% over the past 5 years, which puts real weight on...